ReviewPhysiology (Bethesda, Md.)2014
The genetic basis of chronic mountain sickness.
Review in Physiology (Bethesda, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Chronic high-altitude exposure and intracerebral hemorrhage: A novel perspective from the vascular-immune-neuronal network.Neuroprotection (Chichester, England) · 2026Review
- Article
- DNA methylation in adaptation to high-altitude environments and pathogenesis of related diseases.Human genomics · 2025Review
- [Progress in multiomics research on high altitude polycythemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Deep phenotyping of 11,880 highlanders reveals novel adaptive traits in native Tibetans.iScience · 2023Article
- Arginine attenuates chronic mountain sickness in rats via microRNA-144-5p.Mammalian genome : official journal of the International Mammalian Genome Society · 2023Article
- Evidence of the interplay of genetics and culture in Ethiopia.Nature communications · 2021Article
- Study of Brain Structure and Function in Chronic Mountain Sickness Based on fMRI.Frontiers in neurology · 2021Article
- Pharmacokinetics of Acetaminophen and Metformin Hydrochloride in Rats After Exposure to Simulated High Altitude Hypoxia.Frontiers in pharmacology · 2021Article
- High-altitude adaptation: Role of genetic and epigenetic factors.Journal of biosciences · 2021Review
- Increased hypoxic proliferative response and gene expression in erythroid progenitor cells of Andean highlanders with chronic mountain sickness.American journal of physiology. Regulatory, integrative and comparative physiology · 2020Article
- The Genetic Architecture of Chronic Mountain Sickness in Peru.Frontiers in genetics · 2019Article
- Triggers, Protectors, and Predictors in Episodic Migraine.Current pain and headache reports · 2018Review
- Mitochondrial dysfunction in iPSC-derived neurons of subjects with chronic mountain sickness.Journal of applied physiology (Bethesda, Md. : 1985) · 2018Article
- Carotid Bodies and the Integrated Cardiorespiratory Response to Hypoxia.Physiology (Bethesda, Md.) · 2018Review
- High-altitude adaptation in humans: from genomics to integrative physiology.Journal of molecular medicine (Berlin, Germany) · 2017Review
- The prevalence of pulmonary hypertension in patients with obesity hypoventilation syndrome: a prospective observational study.Journal of thoracic disease · 2017Article
- Senp1 drives hypoxia-induced polycythemia via GATA1 and Bcl-xL in subjects with Monge's disease.The Journal of experimental medicine · 2016Article
- Ancient DNA reveals selection acting on genes associated with hypoxia response in pre-Columbian Peruvian Highlanders in the last 8500 years.Scientific reports · 2016Article
- New genetic and physiological factors for excessive erythrocytosis and Chronic Mountain Sickness.Journal of applied physiology (Bethesda, Md. : 1985) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chronic mountain sickness (CMS) is a disease that affects many high-altitude dwellers, particularly in the Andean Mountains in South America. The hallmark symptom of CMS is polycythemia, which causes increased risk of pulmonary hypertension and stroke (among other symptoms). A prevailing hypothesis in high-altitude medicine is that CMS results from a population-specific "maladaptation" to the hypoxic conditions at high altitude. In contrast, the prevalence of CMS is very low in other high-altitude populations (e.g., Tibetans and Ethiopians), which are seemingly well adapted to hypoxia. In recent years, concurrent with the advent of genomic technologies, several studies have investigated the genetic basis of adaptation to altitude. These studies have identified several candidate genes that may underlie the adaptation, or maladaptation. Interestingly, some of these genes are targeted by known drugs, raising the possibility of new treatments for CMS and other ischemic diseases. We review recent discoveries, alongside the methodologies used to obtain them, and outline some of the challenges remaining in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.